Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Troglitazone

C M Spencer1, A Markham

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

Troglitazone effectively lowers blood sugar and improves insulin sensitivity in patients with non-insulin-dependent diabetes mellitus (NIDDM). This medication also reduces cardiovascular risk factors, demonstrating a favorable safety profile in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cabotegravir Plus Rilpivirine: First Approval.

Drugs·2020
Same author

Benralizumab: First Global Approval.

Drugs·2018
Same author

Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

CNS drugs·2016
Same author

Erratum to: Pergolide: a review of its pharmacology and therapeutic use in Parkinson's disease.

CNS drugs·2016
Same author

Erratum to: Ziprasidone.

CNS drugs·2016
Same author

Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

CNS drugs·2016
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Non-insulin-dependent diabetes mellitus (NIDDM) is characterized by insulin resistance.
  • Elevated proinsulin and triglyceride levels are significant cardiovascular disease risk factors in NIDDM patients.

Purpose of the Study:

  • To evaluate the efficacy of troglitazone in improving glycemic control and reducing cardiovascular risk factors in patients with NIDDM.
  • To assess the safety and tolerability of troglitazone in NIDDM patients.

Main Methods:

  • Clinical trials were conducted using troglitazone dosages ranging from 200 to 800 mg daily.
  • Troglitazone was administered alone or in combination with other oral antidiabetic agents or insulin.
  • Comparisons were made against baseline and placebo groups in patients with NIDDM refractory to other treatments.

Related Experiment Videos

Main Results:

  • Troglitazone significantly reduced plasma/serum glucose levels and glycosylated haemoglobin compared to baseline and placebo.
  • Troglitazone demonstrated a reduction in elevated proinsulin and triglyceride levels.
  • Adverse event incidence in US patients receiving troglitazone was comparable to placebo recipients.

Conclusions:

  • Troglitazone effectively improves insulin sensitivity and glycemic control in NIDDM patients.
  • Troglitazone offers a potential therapeutic option for managing cardiovascular risk factors in NIDDM.
  • Troglitazone was generally well-tolerated, suggesting a favorable safety profile.